PTHS PTHS Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)

Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies

HRO

HarrowHROW

$94.64M+41.8%

LifeMD, Inc.LFMD

$34.48M+0.2%

Zevra Therapeutics, Inc.ZVRA

——

Other financials

Income statement

See full

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

See full

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

See full

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation

See full

Market cap$98.22M+75.4%

Enterprise value$95.89M—

P/S3.6×—

Profitability

See full

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Returns & leverage

See full

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's total cash, cash equivalents, and restricted cash (inclusive).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTHS's total cash, cash equivalents, and restricted cash (inclusive)?: PTHS (PTHS) reported total cash, cash equivalents, and restricted cash (inclusive) of $32.23M in Q1 2026.